Diabetes
From the Journals
Troponin to ID diabetes patients with silent heart disease?
“What we are seeing is that many people with type 2 diabetes who have not had a heart attack or a history of cardiovascular disease are at high...
News from the FDA/CDC
FDA approves new drug, sotagliflozin, for heart failure
“It will be a reasonably tall task for sotagliflozin to come from behind and be disruptive in a space where there are already two well-established...
From the Journals
Diabetes, cholesterol meds use drops after bariatric surgery
Undergoing bariatric surgery was associated with a substantial and long-lasting reduction in the use of lipid-lowering and antidiabetic...
From the Journals
CGM completes picture of A1c in type 2 diabetes
“This may help empower people with diabetes to better manage their condition, giving them practical insights into the factors driving daily...
Conference Coverage
New AACE type 2 diabetes algorithm individualizes care
Splitting the glucose-lowering algorithms into “complications-centric” and “glucose-centric” graphics is new.
Commentary
Why the approval of MiniMed 780G is a ‘quantum leap’ forward
The FDA approval of the MiniMed 780G artificial pancreas promises better glucose control in patients with type 1 diabetes, and Dr. Ann Peters is “...
Conference Coverage
Expert discusses which diets are best, based on the evidence
The Mediterranean diet is not only helpful for losing weight but also can reduce the risk of various chronic diseases.
From the Journals
Lifestyle med experts tell how to deprescribe diabetes meds
Medication de-escalation methods used by lifestyle medicine providers when patients show a decreased need for diabetes medications are described...
Conference Coverage
Medications provide best risk-to-benefit ratio for weight loss, says expert
Surgery provides the most weight loss, but has the greatest risk, according to an endocrinology, diabetes, and metabolism professor.
Conference Coverage
Can an endoscopic procedure treat type 2 diabetes?
This process is thought to improve insulin sensitivity, in part, by altering gut hormones and nutritional sensing,
Feature
Tirzepatide scores win in second obesity trial, SURMOUNT-2
Tirzepatide (Mounjaro) met its primary endpoints, compared with placebo, in the SURMOUNT-2 trial, designed to test weight-loss efficacy, in top-...